<![CDATA[Roundup: Alcon Acquires Neurotech and Encelto, Ai Proteins Enters Research Collaboration and License Agreeme...
Alcon Expands Its Cell Therapy Ambitions With $550M Neurotech Pharma Acquisition
Alcon’s Neurotech Pharmaceuticals acquisition brings the rare vision disorder cell therapy Encelto as well as the platform technology that developed it. Last year, Alcon acquired a...
The World’s Next Breakthrough in Eye Care Isn’t Just Innovation. It’s Capacity.
Few things are more fundamental to human potential than the ability to see. Sight helps us connect with others, navigate the world and live independently. Yet, a gap between what i...
J&J bets $2.2B on Ollin’s vision loss drug
The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.
J&J’s $2.2B Ollin Buyout Brings Late-Stage Eye Drug; Blackstone Deal Adds Trial Funding
Johnson & Johnson’s Ollin Biosciences acquisition comes with a Phase 3-ready bispecific antibody. The companies say this eye drug offers advantages over Vabysmo, a Roche drug a...
Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data
Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal p...
Over Half a Million Eye Drops Recalled. See Affected Products
The FDA says this Class II recall could cause temporary or medically reversible harm; users should match product details against the agency's enforcement report.
Surmodics Launches IOL Cartridge Coating Automation Center in Horsham
New center combines advanced hydrophilic coating technology, IOL cartridge application expertise and automated processing to support scalable ophthalmic device manufacturing
Almost 750,000 eye drop products, many sold at Walgreens, recalled over 'sterility' concerns
Hundreds of thousands of eye drop products are being recalled under the U.S. Food and Drug Administration's second-highest risk category, according to a recent update.
Experimental Cataract Lens Can Treat Glaucoma Through Time-Release Drugs
TUESDAY, Oct. 13, 2026 — An experimental cataract lens also can help treat a person’s glaucoma, new clinical trial results show. The artificial lenses carry small pads of a widely...
SpyGlass Pharma reports 4-year glaucoma implant trial results
Federal judge certifies class action lawsuit against Hubble Contacts
Lawsuit alleges Hubble deceived customers into purchasing contact lenses their eye doctors never prescribed.
Merck reveals study success, and possible safety worries, for eye drug hopeful
A medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies in diabetic macular edema, though language regarding the drug’s safety stirred debate...
Over 4.8 million eye drop products recalled nationwide: FDA
TOPEKA (KSNT) – Federal officials report that a company is recalling over 4.8 million eye drop products nationwide due to concerns regarding their sterility. Officials with the Foo...
Shifting the standard: myopia companies to look out for
Medicines are under review in the clinic to treat myopia. Here are five myopia companies in sight of approval for their therapies. The post Shifting the standard: myopia companies...
Bausch + Lomb: 3 Key Takeaways for Long-Term Investors
Premium product adoption is lifting margins faster than revenue growth, a sign of pricing power in a competitive market.
AOA's 31 in 31 campaign fights to keep contact lens wearers safe
Take action today to protect patients from illegal and unsafe contact lens sales. The AOA’s 31 in 31 campaign raises awareness for contact lens safety.
<![CDATA[Roundup: CSL & Alentis Enter Global Partnership, Jiangsu Nhwa Enters Global Licensing Deal with Somniver...
<![CDATA[Bausch + Lomb Appoints Thomas Appio as Interim CEO ]]>
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease - Slideshow
VisionLab Brings IOT’s Light-Form Technology To Spanish Consumers
IOT, a Spanish technology company specializing in advanced optical innovation, has developed Light-Form Technology™, a new manufacturing technology that produces ophthalmic lenses...
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.